CMPS
NASDAQ HealthcareCOMPASS Pathways Plc - American Depository Shares
Medical Care Facilities
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
๐ Market Data
| Price | $12.43 |
|---|---|
| Volume | 11,876,621 |
| Market Cap | 1.68B |
| Beta | 2.490 |
| RSI (14-Day) | 42.4 |
| 200-Day MA | $7.94 |
| 50-Day MA | $12.11 |
| 52-Week High | $15.40 |
| 52-Week Low | $3.83 |
| Forward P/E | -11.46 |
| Price / Book | 5.13 |
๐ฏ Investment Strategy Scores
CMPS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (96/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (3/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CMPS in your text
Paste any article, transcript, or post โ the tool will extract CMPS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.